Serum Profiling Assays

Pan-cancer and cancer-specific Microarray Antigen panels for Measuring Humoral Immune Response

The Serametrix Serum Profiling Assay measures patient serum antibodies against proprietary panels of tumor-specific antigens. Measuring the patient’s baseline and post-treatment anti-tumor immune response is pivotal for successful clinical development of novel cancer therapies. Drugs that induce a broad-based immune response in the days and weeks following administration are more likely to meet the clinical end-points required for development and regulatory approval starting with baseline measurements correlated to clinical outcome taht may assist clinicians in identifying patients that are most likely to respond. 

This high-quality ELISA-based service allows precise quantitation of anti-tumor antibodies to tumor antigens either from our antigen portfolio or again as a custom offering. Our ELISA platform allows more quantitative anti-tumor antigen analysis detecting small changes in antibody levels. Our precise assays can measure serum conversion events as well as small changes in antigen type. Serametrix ELISA technology is available as a CLIA service for clinical application and a CLIA ELISA service for patient screening, enrolment, and patient stratification.

The Importance of NY-ESO-1

The ELISA-based test provides a quantitative measure of serum antibody to NY-ESO-1. NY-ESO-1 has been shown to be expressed not only in melanoma but also in cancers of the lung, breast, ovarian, prostate and others. NY-ESO-1 belongs to a class of important tumor antigens known as Cancer/Testis (CT) Antigens. Like other CT antigens, NY-ESO-1 expression in adult non-germline tissue is limited to tumors. Not only are these antigens attractive drug targets but also their corresponding antibodies in serum have been shown to correlate with clinical events in cancer patients.

Assay Formats and Cancer Types

Serum Profiling Assays are available as protein microarrays with full-length human tumor-associated antigens or ELISA immunoassays for NY-ESO-1 and other tumor antigens are available for the following cancer types:

  • Breast cancer
  • Colorectal cancer
  • Glioblastoma
  • Melanoma
  • Non-small cell lung cancer
  • Pancreatic cancer
  • Prostate cancer
  • Renal cell carcinoma
  • Ovarian cancer

Serum Profiling Assay Components

The Serametrix Serum Profiling Assay includes study design, serum profiling, and results with comprehensive analysis and interpretation, with expertise to help to define next steps and further studies.

To discuss ideas for your study or request a quote, click here.

©2019 Serametrix l US: +1-760-652-4060 l Europe: +44 (0)20 8973 3853 | info@serametrix.com